Small Bowel Adenocarcinoma: Is there a difference in survival for Crohn's versus Sporadic cases?
It is well known that Crohn's disease is a risk factor for the development of small bowel adenocarcinoma. However, the association between Crohn's disease-associated small bowel adenocarcinoma and survival is less understood. The goal of this study is to determine the impact of Crohn's disease on survival in small bowel adenocarcinoma. Patients with small bowel adenocarcinoma, either associated with Crohn's disease or diagnosed sporadic, were identified in the National Cancer Database from 2004-2016. The primary outcome is overall survival. Of 2,668 patients, 493 had Crohn's disease-associated small bowel adenocarcinoma and 2,175 had sporadic small bowel adenocarcinoma. Crohn's disease patients were more likely to present at a younger age (62 vs 65, p<0.001), have tumors located in the ileum (62.7% vs 25.0%, p<0.001), and have poorly differentiated tumors (47.0% vs 31.7%, p<0.001) compared to sporadic small bowel adenocarcinoma. Factors associated with significantly decreased survival included older age (HR:1.02, 95%CI:1.02-1.03, p<0.001), higher Charlson score (HR:1.39, 95%CI:1.13-1.72, p=0.002), higher tumor grade (HR:1.09, 95%CI:1.04-1.14, p<0.001), positive surgical margins (HR:1.60, 95%CI:1.39-1.84, p<0.001), and higher stage of disease (HR:1.90, 3.75, 8.13, 95%CI:1.37-2.64, 2.68-5.24, 5.77-11.47, for II, III, IV, respectively, compared to I, all p<0.001) (Table 3). Receipt of chemotherapy was associated with significantly improved survival (HR:0.61, 95%CI:0.53-0.70, p<0.001). CD (HR:1.01, 95%CI: 0.99-1.02, p=0.39), was not significantly associated with survival. Compared to sporadic patients, Crohn's disease patients have similar overall survival and Crohn's disease is not an independent risk factor for mortality.